Enspryng (satralizumab)


Enspryng is approved as a monotherapy or as an add-on therapy to baseline immunosuppressant therapy, for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescent patients who are aquaporin-4 antibody (AQP4-IgG) seropositive.

Enspryng is a monoclonal antibody, administered subcutaneously every four weeks. that targets the interleukin-6 (IL-6) receptor. IL-6 is a signalling protein, produced by immune cells in the body, that is believed to play a key role in the inflammation occurring in people with NMOSD, leading to unpredictable and severe relapses.

Enspryng was designed by Chugai using novel antibody recycling technology, which allows for longer duration of antibody circulation and maximum inhibition of IL-6 signalling, while minimising safety risks in a chronic disease setting.

Enspryng is currently licensed in Canada and Japan and remains an investigational treatment in all other jurisdictions.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.